Renal cell carcinoma
Conditions
Interventions
Observation group:None
Sponsors
Zhejiang Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with renal cell carcinoma (RCC) who are highly suspected based on pathological or imaging findings and are planned for surgical resection, meeting the clinical diagnostic criteria for locally advanced or high-risk kidney cancer; 2. Planned to undergo radical or partial nephrectomy, with postoperative adjuvant therapy (such as targeted therapy or immunotherapy) considered based on specific conditions; 3. Complete preoperative clinical evaluation data, including imaging examinations (such as contrast-enhanced CT, MRI, renal dynamic imaging, etc.) and laboratory indicators (such as renal function, tumor markers); 4. Age >=18 years, no restrictions on gender; 5. No other active malignancies and no serious comorbidities that would affect the safety of surgery or adjuvant therapy; 6. Confirmed by a multidisciplinary team (MDT) consultation that the patient can undergo surgery and subsequent individualized adjuvant therapy.
Exclusion criteria
Exclusion criteria: 1. Patients with non-renal cell carcinoma, or those with an unclear pathological diagnosis; 2. Patients who have previously received systemic targeted therapy, immunotherapy, or radiotherapy, and are currently in a recurrent or widely metastatic stage; 3. Patients with severe cardiac or pulmonary dysfunction, liver or kidney failure, active infections, etc., who cannot tolerate surgery or adjuvant therapy; 4. Patients with severe psychiatric disorders, cognitive impairment, or other conditions affecting study compliance; 5. Patients unable to cooperate with postoperative follow-up or expected to be unable to complete relevant assessments and data collection during the study period; 6. Patients currently participating in other interventional clinical studies that may interfere with the evaluation of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Accuracy of pathological risk classification; | — |
Secondary
| Measure | Time frame |
|---|---|
| Model calibration performance;Net clinical benefit by decision curve analysis;Predictive performance for molecular subtyp; | — |
Countries
China
Contacts
Public ContactQi Zhang
Zhejiang Provincial People's Hospital
Outcome results
None listed